| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | -212.92% | -3.46% | -225066.67% | -2698.78% | -1627.03% | — |
| EBITDA Margin | -211.30% | -3.35% | -224733.33% | -2674.54% | -1623.16% | — |
| Net Margin | -203.25% | 8.97% | -181216.67% | -2635.41% | -1625.10% | — |
| Current Ratio | 7.28 | 14.26 | 96.92 | 51.01 | 17.56 | 40.69 |
| Quick Ratio | 6.48 | 14.04 | 96.92 | 51.01 | 17.56 | 40.69 |
| Debt / Equity | 0.84 | 0.00 | — | — | — | — |
| ROE | -149.92% | 3.11% | -23.56% | -12.71% | -28.51% | -8.61% |
| ROA | -52.28% | 2.28% | -23.31% | -12.32% | -26.83% | -8.35% |
| Asset Turnover | 0.26 | 0.25 | 0.00 | 0.00 | 0.02 | — |
| Book Value / Share | 1.16 | 2.51 | 2.42 | 6.83 | 10.87 | — |
Ars Pharmaceuticals Inc. specializes in the biopharmaceutical sector, focusing on the development of innovative, self-administered therapeutics aimed at improving patient outcomes. The company's primary purpose is to advance medical solutions for allergy-related indications, enhancing safety and convenience for patients affected by conditions such as allergic reactions requiring rapid intervention. Notable for its emphasis on creating user-friendly delivery mechanisms, Ars Pharmaceuticals tailors its offerings to both patients and healthcare professionals seeking reliable and effective emergency treatments. By addressing critical needs within the healthcare industry, Ars Pharmaceuticals plays a significant role in expanding options in allergy treatment and management. Its contributions to the medical field underscore its ongoing commitment to transforming therapeutic landscapes and meeting pressing health challenges.